Advertisement

Breast Cancer Research and Treatment

, Volume 29, Issue 1, pp 127–138 | Cite as

The epidermal growth factor receptor as a target for therapy in breast carcinoma

  • Jose Baselga
  • John Mendelsohn
Guest editor's introduction

Summary

The epidermal growth factor (EGF) receptor and its ligands have an important regulatory role in breast carcinoma. We have produced a series of monoclonal antibodies (MAbs) directed against the external portion of the EGF receptor. These MAbs prevent the binding of the ligands to the receptor, block ligand-induced activation of the receptor, and can inhibit the growth of breast cancer cells both in tissue culture and in human tumor xenografts in nude mice. We have also shown that anti-EGF receptor antibodies greatly enhance the antitumor effects of chemotherapeutic agents active in breast cancer. Phase I clinical trials with single doses of MAb conducted in patients with tumors over-expressing EGF receptors demonstrated favorable pharmacokinetics, good tumor imaging, and a lack of toxicity. A human:murine chimeric antibody has been produced with comparable affinity and antitumor activity that will enable us to administer repeated doses of MAb either alone or in combination with chemotherapy. Our pre-clinical data support the concept that the EGF receptor may be an optimal target for treatment with receptor blocking antibodies, either alone or in combination with chemotherapy.

Key words

EGF receptor monoclonal antibodies clinical trials humanized antibodies chemotherapy imaging 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Barnes D, Sato G: Serum-free cell culture: a unifying approach. Cell 22:649–655, 1980.Google Scholar
  2. 2.
    Weinberg RA (ed): Oncogenes and the Molecular Origin of Cancer. Cold Spring Harbor Laboratories Press, Cold Spring Harbor, 1989.Google Scholar
  3. 3.
    Rosenthal A, Lindquist PB, Bringman TS, Goeddel DV, Derynck R: Expression in rat fibroblasts of a human transforming growth factor-alpha cDNA results in transformation. Cell 46:301–309, 1986.Google Scholar
  4. 4.
    DiFiore PP, Pierce JH, Fleming TP, Hazan R, Ullrich A, King CR, Schlessinger J, Aaronson SA: Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell 51:1063–1070, 1987.Google Scholar
  5. 5.
    Velu TJ, Beguinot L, Vass WC, Zhang K, Pastan I, Lowy DR: Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. Science 238:1408–1410, 1987.Google Scholar
  6. 6.
    Derynck R, Goeddel DV, Ullrich A, Gutterman JU, Williams RD, Bringman TS, Berger WH: Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res 47:707–712, 1987.Google Scholar
  7. 7.
    Ozanne B, Richards CS, Hendler F, Burns D, Gusterson B: Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas. J Pathol 149:9–14, 1986.Google Scholar
  8. 8.
    Carpenter G: Receptors for epidermal growth factor and other polypeptide mitogens. Ann Rev Biochem 56:881–914, 1987Google Scholar
  9. 9.
    Plowman GD, Whitney GS, Neubauer MG, Green JM, McDonald VL, Todaro GJ, Shoyab M: Molecular cloning and expression of an additional epidermal growth factor receptor-related gene. Proc Natl Acad Sci USA 87:4905–4909, 1990.Google Scholar
  10. 10.
    Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsburn M: A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 251:936–939, 1991.Google Scholar
  11. 11.
    Jhappan C, Stahle C, Harkins RN, Fausto N, Smith GH, Merlino GT: TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 61:1137–1146, 1990.Google Scholar
  12. 12.
    Matsui Y, Halter SA, Holt JT, Hogan BL, Coffey RJ: Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell 61:1147–1155, 1990.Google Scholar
  13. 13.
    Sandgren EP, Luetteke NC, Palmiter RD, Brinster RL, Lee DC: Overexpression of TGF alpha in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 61:1121–1135, 1990.Google Scholar
  14. 14.
    Fitzpatrick SL, LaChance MP, Schultz GS: Characterization of epidermal growth factor receptor and action on human breast cancer cells in culture. Cancer Res 44:3442–3447, 1984.Google Scholar
  15. 15.
    Perez R, Pascual M, Macias A, Lage A: Epidermal growth factor receptors in human breast cancer. Breast Cancer Res Treat 4:189–193, 1984.Google Scholar
  16. 16.
    Sainsbury JRC, Sherbet GV, Farndon JR, Harris AL: Epidermal growth factor receptors and oestrogen receptors in human breast cancer. Lancet i:364–366, 1985.Google Scholar
  17. 17.
    Harris AL, Nicholson S, Sainsbury JRC, et al: Epidermal growth factor receptor: A marker of early relapse in breast cancer and tumor stage progression in bladder cancer; interactions withneu. In: Furth M, Greaves M (eds) The Molecular Diagnostics of Human Cancer. Cold Spring Harbor Laboratory, Cold Spring Harbor NY, 1989, Cancer Cells 7, pp 353–357.Google Scholar
  18. 18.
    Sainsbury JRC, Malcolm AJ, Appleton DR, Farndon JR, Harris AL: Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. J Clin Pathol 38:1225–1228, 1985.Google Scholar
  19. 19.
    Dickson RB, Bates SE, McManaway ME, Lippman ME: Characterization of estrogen responsive transforming activity in human breast cancer cell lines. Cancer Res 46:1707–1713, 1986.Google Scholar
  20. 20.
    Dickson RB, Huff KK, Spencer EM, Lippman ME: Induction of epidermal growth factor-related polypeptides by 17β-estradiol in MCF-7 human breast cancer cells. Endocrinology 118:138–142, 1985.Google Scholar
  21. 21.
    LeJeune S, Leek R, Horak E, Plowman G, Greenall M, Harris AL: Amphiregulin, epidermal growth factor receptor, and estrogen receptor expression in human primary breast cancer. Cancer Res 53:3597–3602, 1993.Google Scholar
  22. 22.
    Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH, Mendelsohn J: Growth stimulation of A431 cells by EGF: Identification of high affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci USA 80:1337–1341, 1983.Google Scholar
  23. 23.
    Sato J.D, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH: Biological effectin vitro of monoclonal antibodies to human EGF receptors. Mol Biol Med 1:511–529, 1983.Google Scholar
  24. 24.
    Gill GN, Kawamoto T, Cochet C, Le A, Sato JD, Masui H, MacLeod CL, Mendelsohn J: Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 259:7755–7760, 1984.Google Scholar
  25. 25.
    Sunada H, Magun B, Mendelsohn J, MacLeod CL: Monoclonal antibody against EGF receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci USA 83:3825–3829, 1986.Google Scholar
  26. 26.
    Sunada H, Yu P, Peacock JS, Mendelsohn J: Modulation of tyrosine serine and threonine phosphorylation and intracellular processing of the epidermal growth factor receptor by anti-receptor monoclonal antibody. J Cell Physiol 142:284–292, 1990.Google Scholar
  27. 27.
    Markowitz SD, Molkentin K, Gerbic C, Jackson J, Stellato T, Willson JKV: Growth stimulation by coexpression of transforming growth factor α and epidermal growth factor-receptor in normal and adenomatous human colon epithelium. J Clin Invest 86:356–362, 1990.Google Scholar
  28. 28.
    Vande Woude GF, Schulz N, Zhou R, Paules RS, Daar I, Yew N, Oskarsson M: Cell cycle regulation, oncogenes, and antineoplastic drugs.In: Fortner JG, Rhoads JE (eds) Accomplishments in Cancer Research, General Motors Cancer Research Foundation. J.B. Lippincott Co., Philadelphia, 1990, pp 128–143.Google Scholar
  29. 29.
    Kawamoto T, Mendelsohn J, Le A, Sato GH, Lazar CS, Gill GN: Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells. J Biol Chem 259:7761–7766, 1984.Google Scholar
  30. 30.
    Arteaga CL, Coronado E, Osborne CK: Blockade of the epidermal growth factor receptor inhibits transforming growth factor α-induced but not estrogen-induced growth of hormone-dependent human breast cancer. Mol Endocrinol 2:1064–1069, 1988.Google Scholar
  31. 31.
    Ennis BW, Valverius EM, Lippman ME, Bellot F, Kris R, Schlessinger J, Masui H, Goldenberg A, Mendelsohn J, Dickson RB: Monoclonal anti-EGF receptor antibodies inhibit the growth of malignant and non-malignant human mammary epithelial cells. Mol Endocrinol 3:1830–1838, 1989.Google Scholar
  32. 32.
    Bates SE, Valverius EM, Ennis BW, Bronzert DA, Sheridan JP, Stampfer MR, Mendelsohn J, Lippman ME, Dickson RB: Expression of the TGFα/EGF receptor pathway in normal human breast epithelial cells. Endocrinol 126:596–607, 1990.Google Scholar
  33. 33.
    Karnes WE Jr, Walsh JH, Wu SV, Kim RS, Martin MG, Wong HC, Mendelsohn J, Gazdar AF, Cuttitta F: Autocrine stimulation of EGF receptors by TGFα regulates autonomous proliferation of human colon cancer cells. Gastroenterol 102:474–485, 1992.Google Scholar
  34. 34.
    Ciardiello F, Kim N, Jaggi R, Redmond S, Liscia DS, Sanfilippo B, Merlo G, Callahan R, Kidwell WR, Salomon DS: Induction of transforming growth factor α expression in mouse mammary epithelial cells after transformation with a point-mutated-c-Ha-ras proto-oncogene. Mol Endocrinol 2:1202–1216, 1988.Google Scholar
  35. 35.
    Ciardiello F, McGeady ML, Kim N, Basolo F, Hynes N, Langton BC, Yokozaki H, Saeki T, Elliot JW, Masui H, Mendelsohn J, Soule H, Russo J, Salomon DS: TGFα expression in enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu proto-oncogene, and overexpression of the TGFα cDNA leads to transformation. Cell Growth Differen 1:407–420, 1990.Google Scholar
  36. 36.
    Masui H, Kawamoto T, Sato JD, Wolf B, Sato GH, Mendelsohn J: Growth inhibition of human tumor cells in athymic mice by anti-EGF receptor monoclonal antibodies. Cancer Res 44:1002–1007, 1984.Google Scholar
  37. 37.
    Masui H, Boman B, Hyman J, Castro L, Mendelsohn J: Treatment with anti-EGF receptor monoclonal antibody causes regression of DiFi human colorectal carcinoma xenografts [Abs. #2340]. Proc AACR 32:394, 1991.Google Scholar
  38. 38.
    Atlas I, Mendelsohn J, Baselga J, Fair W, Kumar R: Growth regulation of human renal carcinoma cells: Role of transforming growth factor-α. Cancer Res 52:3335–3339, 1992.Google Scholar
  39. 39.
    Fan Z, Masui H, Atlas I, Mendelsohn J: EGF receptor function can be blocked by both bivalent and monovalent fragments of 225 anti-EGF receptor monoclonal antibody. Cancer Res, in press, 1993.Google Scholar
  40. 40.
    Mendelsohn J: Potential clinical applications of anti-EGF receptor monoclonal antibodies.In: Furth M, Greaves M (eds) The Molecular Diagnostics of Human Cancer. Cold Spring Harbor Laboratory Press, Cold Spring Harbor NY, 1989. Cancer Cells 7, pp 359–362.Google Scholar
  41. 41.
    Modjtahedi H, Styles J, Dean C: The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468. Br J Cancer 67:247–253, 1993.Google Scholar
  42. 42.
    Modjtahedi H, Eccles S, Box G, Styles J, Dean C: Immunotherapy of human tumour xenografts over-expressing the EGF receptor with rat antibodies that block growth factor-receptor interaction. Br J Cancer 67:254–261, 1993.Google Scholar
  43. 43.
    Mendelsohn J, Masui H, Goldenberg A: Anti-epidermal growth factor receptor monoclonal antibodies may inhibit A431 tumor cell proliferation by blocking an autocrine pathway. Trans Assoc Amer Phys 100:173–178, 1987.Google Scholar
  44. 44.
    Goldenberg A, Masui H, Divgi C, Kamrath H, Pentlow K, Mendelsohn J: EGF receptor overexpression and localization of nude mouse xenografts using111Indium labelled anti-EGF receptor monoclonal antibody. J Natl Cancer Inst 81:1616–1625, 1989.Google Scholar
  45. 45.
    Markowitz SD, Molkentin K, Gerbic C, Jackson J, Stellato T, Willson JKV: Growth stimulation by coexpression of transforming growth factor α and epidermal growth factor-receptor in normal and adenomatous human colon epithelium. J Clin Invest 86:4356–362, 1990.Google Scholar
  46. 46.
    Valverius EM, Bates SE, Stampfer ME, Clark R, McCormick F, Salomon DS, Lippman ME, Dickson RB: Transforming growth factor-α production and epidermal growth factor receptor expression in normal and oncogene transformed human mammary epithelial cells. Mol Endocrinol 3:203–214, 1989.Google Scholar
  47. 47.
    Aboud-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J, Sela M: Efficacy of antibodies to epidermal growth factor receptor against KB carcinomain vitro and in nude mice. J Natl Cancer Inst 21:1605–1611, 1988.Google Scholar
  48. 48.
    Tritton TR: Cell surface actions of Adriamycin. Pharmac Ther 49:293–309, 1991.Google Scholar
  49. 49.
    Marks DI, Fox RM: DNA damage, poly (ADP-ribosyl)ation and apoptotic cell death as a potential common pathway of cytotoxic drug action. Biochem Pharmacol 42:1859–1867, 1991.Google Scholar
  50. 50.
    Barry MA, Behnke CA, Eastman A: Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 40:2353–2362, 1990.Google Scholar
  51. 51.
    Williams GT, Smith CA, Spooncer E, Dexter TM, Taylor DR: Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature 343:76–79, 1990.Google Scholar
  52. 52.
    Henderson CI: Chemotherapy for metastatic disease.In: Harris JR, Hellman S, Henderson CI, Kinne DW (eds) Breast Diseases. J.B. Lippincott, Philadelphia, 1991, pp 604–665.Google Scholar
  53. 53.
    Zuckier G, Tritton TR: Adriamycin causes upregulation of epidermal growth factor receptor in actively growing cells. Exp Cell Res 148:155–161, 1983.Google Scholar
  54. 54.
    Hanauske AR, Osborne CK, Chamness GC, Clark GM, Forseth BJ, Buchock JB, Arteaga CL, von Hoff DD: Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents. Eur J Cancer Clin Oncol 23:545–551, 1987.Google Scholar
  55. 55.
    Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH, Mendelsohn J: Anti-tumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 85:1327–1333, 1993.Google Scholar
  56. 56.
    Divgi CR, Welt C, Kris M, Real FX, Yeh SDJ, Gralla R, Merchant B, Schweighart S, Unger M, Larson SM, Mendelsohn J: Phase I and imaging trial of indium-111 labeled anti-EGF receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 83:97–104, 1991.Google Scholar
  57. 57.
    Masui H, Morayama T, Mendelsohn J: Mechanism of antitumor activity in mice for anti-EGF receptor monoclonal antibodies with different isotypes. Cancer Res 46:5592–5598, 1986.Google Scholar
  58. 58.
    Baselga J, Scott A, Pfister D, Kris M, Divgi C, Zhang Z, Larson S, Oettgen H, Mendelsohn J: Comparative pharmacology in phase I and imaging trials utilizing anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MAbs) labeled with131I or111In. Proc ASCO 12:368, 1993.Google Scholar
  59. 59.
    Rodeck U, Herlyn M, Herlyn D, Molthoff C, Atkinson B, Varello M, Steplewski Z, Koprowski H: Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: Immunologically mediated and effector cell-independent effects. Cancer Res 47:3692–3696, 1987.Google Scholar
  60. 60.
    Rodeck U, Williams N, Murthy U, Herlyn M: Monoclonal antibody 425 inhibits growth stimulation of carcinoma cells by exogenous EGF and tumor-derived EGF/TGFα. J Cell Biochem 44:69–79, 1990.Google Scholar
  61. 61.
    Perez-Soler R, Donato NJ, Zhang HZ, Shin DM, Brewer HM, Rosenblum MG, Tornos C, Hong WK, Murray JL: Phase I study of anti-epidermal growth factor receptor monoclonal antibody RG83852 in patients with non-small cell lung cancer. Proc ASCO 11:254, 1992.Google Scholar
  62. 62.
    Brady LW, Woo DV, Marko A, Dadparvar S, Karlsson U, Rackover M, Peyster R, Emrich J, Miyamoto C, Steplewski Z, Koprowski H: Treatment of malignant gliomas with125I-labeled monoclonal antibody against epidermal growth factor receptor. Antibody Immun Radiopharm 3:169–179, 1990.Google Scholar
  63. 63.
    Waterfield MD, Mayes ELV, Stroobant P, Bennett PLP, Young S, Goodfellow PN, Banting GS, Ozanne B: A monoclonal antibody to the human epidermal growth factor receptor. J Cell Biochem 20:149–161, 1982.Google Scholar
  64. 64.
    Kalofonos HP, Pawlikowska TR, Hemingway A, Courtenay-Luck N, Dhokia B, Snook D, Sivolapenko GB, Hooker GR, McKenzie CG, Lavendar PJ: Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. J Nucl Med 30:1636–1645, 1989.Google Scholar
  65. 65.
    Drebin JA, Link VC, Greene MI: Monoclonal antibodies reactive with distinct domains of theneu oncogene-encoded p185 molecule exert synergistic anti-tumor effectsin vivo. Oncogene 2:273–277, 1988.Google Scholar
  66. 66.
    Kasprzyk PG, Song SU, DiFiore PP, King CR: Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res 52:2771–2776, 1992.Google Scholar
  67. 67.
    White S, Taetle R, Seligman PA, Rutherford M, Trowbridge IS: Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cells growthin vitro andin vivo: Evidence for synergistic antiproliferative effects. Cancer Res 50:6295–6301, 1990.Google Scholar
  68. 68.
    Arteaga CL: Interference of the IGF system as a strategy to inhibit breast cancer growth. Breast Cancer Res Treat 22:101–106, 1992.Google Scholar
  69. 69.
    Bates SE, Davidson NE, Valverius EM, Freter CE, Dickson RB, Tam JP, Kudlow JE, Lippman ME, Salomon DS: Expression of transforming growth factor-α and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. Mol Endocrinol 2:543–555, 1988.Google Scholar
  70. 70.
    Ciardiello F, Kim N, Liscia DS, Bianco C, Lidereau R, Merlo G, Callahan R, Greiner J, Szpak C, Kidwell W, Schlom J, Salomon DS: mRNA expression of transforming growth factor alpha in human breast carcinomas and its activity in effusions of breast cancer patients. J Natl Cancer Inst 81:1165–1171, 1989.Google Scholar

Copyright information

© Kluwer Academic Publishers 1994

Authors and Affiliations

  • Jose Baselga
    • 1
  • John Mendelsohn
    • 1
  1. 1.Laboratory of Receptor Biology and Department of MedicineMemorial Sloan-Kettering Cancer Center and Cornell University Medical CollegeNew YorkUSA

Personalised recommendations